All In Biotech

Drug Trial Radar · NCT07208149

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Sep 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

  • MR001 Bispecific Antibody for InjectionDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Approximately 6 months
  2. Maximum Tolerated Dose (MTD) of MR001Time frame: Approximately 6 months
  3. Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0Time frame: Approximately 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Hunan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.